Innovative Pipeline Oculis has a highly differentiated pipeline with promising late-stage candidates like OCS-01 for diabetic macular edema and inflammation, and OCS-05 for neuroprotection in optic neuritis, indicating strong potential for new ophthalmic treatment solutions.

Upcoming Milestones With the recent completion of the final patient visit in the Phase 3 DIAMOND trial for OCS-01 and expected topline results in June 2026, there is an opportunity to align sales efforts with imminent product launches and clinical data releases.

Unmet Medical Needs Oculis actively highlights unmet needs in non-invasive treatment options for diabetic macular edema and dry eye disease, offering potential sales openings with clinics and hospitals seeking innovative therapies for these prevalent conditions.

Research Engagements Participation in prominent industry events like ARVO demonstrates a focus on scientific validation and key opinion leader engagement, providing avenues to showcase new products and collaborate with healthcare providers in ophthalmology.

Global Market Focus Headquartered in Switzerland with operations extending into the U.S. and Iceland, Oculis has international reach that supports expansion of sales channels across diverse healthcare markets.